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Heparin Induced Thrombocytopenia (HIT)
Heparin is a widely administered for the prevention and treatment of venous and arterial
thromboembolism. Clinicians who prescribe heparin must be prepared to monitor for potential
adverse effects; one of the most important of these is an immunoglobulin-mediated reaction,
heparin induced thrombocytopenia (HIT).
In this brief review all issues related to “HIT’ could not be addressed, therefore the emphasis
would be on the important ones.
Clinical Features: HIT (sometimes known as HIT type II, or immune HIT) is characterized by
thrombocytopenia usually beginning 5-10 days after the start of therapy. Its importance is related
to its paradoxical high risk of thromboembolic events, like peripheral arterial occlusion, acute MI,
stroke and death. In addition DVT and pulmonary embolism are strongly associated with HIT.
Other thrombotic manifestations are adrenal hemorrhagic necrosis leading to hemorrhagic
infarction, dural sinus thrombosis and venous limb gangrene.
The frequency of HIT is 1-3% in patients receiving unfractioned heparin for 1-2 weeks
respectively. Typically the platelet count begins to decrease after 5-10 days after starting therapy
(first day = day zero). It usually decreases by 50% and rarely reaches 10-20 x 10 exp 3/mm.
Usually the count does not recover unless heparin is discontinued, after which it returns to
normal in 4 days in 50% patients and 7 days in 90%, but occasionally requires several weeks for
recovery. Of interest, bleeding complications are rare despite low platelet count and
anticoagulation therapy. The disorder can be triggered by any route or dosage of heparin,
including the flushes administered to maintain patency of IV catheters.
Treatment: Conventionally treatment of HIT requires immediate discontinuation of heparin by any
route or in any dosage.
Warfarin: The role is controversial, since this agent is found associated with the unusual
syndrome of venous limb gangrene in patients with HIT complicated by DVT.
LMWH: These drugs are considered contraindicated in HIT due to cross-reactivity (with
unfractioned heparin UFH), high risk of triggering persistent or recurrent thrombocytopenia with
associated thrombosis, and because other effective treatment options are available. Of interest, it
should be noted that LMWH are less immunogenic than UFH, it is possible that wider use of
LMWH in place of UFH will reduce the risk of HIT.
Treatment Adjuncts: Procedures like limb saving thrombectomy or embolectomy and insertion
of vena caval filters to prevent pulmonary embolism may be considered. Thrombolytic therapy
can be effective in selected patients. Aspirin and other antiplatelet agents have a modest
indication and should not be primary therapy.
Limited experience suggest that plasma pheresis might work particularly HIT patients with DIC
(disseminated intravascular coagulation).

Newer Treatment Strategies;
Recombinant Hirudin; Since no structural similarity with heparin, cross-reactivity is not a
problem. Its effects can be easily monitored by aPTT (target value 1.5-3 times median of normal
range).
Argatroban; A selective antithrombin excreted normally in patients with renal failure and may
therefore be useful in patients with HIT receiving hemodialysis.
Danaparoid; A safe and effective agent in patients on hemodialysis with an advantage of single
IV predialysis injection. Safely used in pregnant patient.
Salwa Ahsan (Staff Pharmacist)
Reference: Pharmacotherpy, vol 19, iss 2 yr 1999
Antibiotics and Dialysis
Antibiotics may be called as life saving agents depending upon the case we are dealing with.
Many times the course of disease is complicated by renal failure and the need of dialysis. In such
a scenario in which antibiotics are needed along with dialysis, one has to keep in mind the
capability of the drug for being dialyzed. For drug, which is removed by dialysis, a supplemental
doses is needed in order to maintain the therapeutic blood levels. Following list would be help full
for optimizing dose of commonly used antibiotics in patients undergoing hemodialysis.
Antibiotics
Ampicillin
**Augmentin
Amikacin
Aztreonam
Amphotericin B
Acyclovir
Cefazolin
Cefixime
Ceftazidime
Ceftriaxone
Cefotaxime
Cefepime
Cephalexin
Ciprofloxacin
Co-trimoxazole
Clarithromycin
Fluconazole
Gentamycin
Levofloxacin
Meropenem
Ofloxacin
Quinine
dialysis
Streptomycin
**Tazocin
Vancomycin
*After Dialysis

Dialyzable
Y
Y
Y
Y
N
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Supplemental Dose (AD)*
500-1000 mg
Oral = 375-625 mg
IV = 0.6-1.2 gm
2/3rd of the normal dose
500 mg
60-100% of low normal dose
2 gm
1 gm
1 gm
1 gm
Initial dose or 250 mg
500 mg
250-500 mg
50 % of maintenance dose
50 % of maintenance dose
100 mg
1-1.7 mg/kg
250 mg
500 mg
100 mg
15 mg/kg Q12 hrly on day of

Y
Y
N
**Brand names (combination product)

1/2 of normal dose
0.75 gm
Y = YES

N = NO

For drugs, which are removed by dialysis, need supplement dose after dialysis in order to
compensate the lost amount. If dialysis session is near to the dose timing, one can hold the dose
and give after dialysis; this will save cost of supplemental dose.
Salwa Ahsan (Staff Pharmacist)

Management of Helicobacter pylori Infection
The bacterium Helicobacter pylori can infect the stomach during childhood and cause lifelong
chronic gastritis, which can lead to peptic ulcer disease. Curing H pylori infection cures ulcer
disease. And since reinfection in adults is extremely rare, adequate treatment permanently cures
this former chronic recurrent, serious disease. If ulcers do not recur neither do ulcer perforation or
bleeding; quality of life increases, sick leave decreases, and less money is spent on visiting the
doctor and drugs.
Selecting a regimen: An evidence based choice of treatment is impossible because we lack
large randomized trials comparing the highly effective regimens. Treatment of H pylori is difficult
because of the rapid development of resistance to antibiotics, especially to metronidazole, which
occurs more commonly in women and patients from developing countries because of previous
treatment for gynecological infections or infective diarrheas. Resistance to clarithromycin may
occur after failed treatment or after use of this drug for other indications such as respiratory tract
infections. Dual treatment with proton pump inhibitors is now obsolete due to lack of efficacy.
Several triple or quadruple therapies have been sufficiently investigated and seem to be able to
cure either 80% (intention to treat) or 90% (per protocol) of patients. The table shows currently
useful treatments, but none has surfaced as the final treatment of choice. Metronidazole and
clarithromycin are the two key antibiotics. Antibiotic resistance against these two drugs, either
primary or induced after treatment, is clinically important.
Regimen based on Clarithromycin
Length of treatment
Component Drugs
7-10 days
PPI* bid + Amoxicillin 1 gm twice daily + Clarithromycin 500 mg twice
daily
Regimen based on Metronidazole
Length of treatment
Component Drugs
7-10 days
PPI* bid + Amoxicillin 500 mg 2-3 times daily + Metronidazole 400 mg
twice daily
First Line treatment:
If metronidazole resistance is likely a proton pump inhibitor in combination with amoxicillin and
clarithromycin given for one week is preferable.
Second line treatment:
After a proved failure with a treatment containing metronidazole, a patient is likely to be colonized
by a resistant strain of H pylori. In this case a proton pump inhibitor should be given in
combination with amoxicillin and clarithromycin for a week, with about 90% success. If H pylori
eradication is unsuccessful after a treatment containing clarithromycin and the patient is likely to
harbour a metronidazole resistant strain of H pylori, then either omeprazole in combination with
amoxicillin and metronidazole or quadruple therapy (PPI* bid + Colloidal Bismuth Citrate 120 mg
qid + Tetracycline 500 mg Q6H + Metronidazole 400 mg Q6H) are the only logical options, with
roughly 75% success. The regimens containing clarithromycin plus metronidazole should be
disfavored as in case of treatment failure the back up plan options will be limited.
What to tell patients? There has been much discussion of H pylori in the media, and many
patients are aware of its ulcerogenic and carcinogenic potential and may request antibacterial
treatment if they are found to be infected. At present there is no evidence to suggest that
screening and treating patients without risk factors will prevent gastric cancer. The risk of
transmission to partners is low in adults, and treatment of the entire family is not warranted.
Whatever treatment is chosen, patients need careful counseling. The reasons for embarking on
the treatment and the importance of compliance despite possible side effects need to be
emphasized, and the possible side effects must be carefully discussed. The need for good
compliance needs special attention, as it is crucial to the success of treatment.
*PPI = Proton Pump Inhibitor (Omeprazole 20 mg bid)
Abdul Qadeer Sajid (Pharmacist)
References: BMJ vol. 323, Nov 2001. BMJ, vol 320, Jan 2000

Story of A Pharmacist In a Busy Pharmacy
A pharmacist, who was working alone in a busy hospital pharmacy, received a stat order for oral
clonidine 1 mg and levodopa 125 mg for a growth hormone stimulation test on an 8year-old child.
Despite significant pressure from the stat order and a backlog of work, the pharmacist, who was
unfamiliar with the test, took time to research the information and discovered that the correct test
dose of clonidine for a pediatric patient was 0.15 mg/meter square.
After calling the physician, the order was changed to clonidine 0.1 mg. Unfortunately, even
successful outcomes like this one may not be widely appreciated if productivity is sacrificed to
enhance patient safety. Nevertheless, numerous errors reported through the USP-ISMP
Medication Errors Reporting Program have resulted when practitioners felt significant pressure to
place productivity above patient safety, especially when faced with inadequate staffing. Institute
for Safe Medication Practices (ISMP).
Heparin is a widely administered for the prevention and treatment of venous and arterial
thromboembolism. Clinicians who prescribe heparin must be prepared to monitor for potential
adverse effects; one of the most important of these is an immunoglobulin-mediated reaction,
heparin induced thrombocytopenia (HIT).
In this brief review all issues related to “HIT’ could not be addressed, therefore the emphasis
would be on the important ones.
ACE inhibitor, diuretic and NSAID: a dangerous combination
The control of hypertension by ACE inhibitors and diuretics and their beneficial effects in heart
failure are antagonised by NSAIDs. Concurrent use of NSAIDs and diuretics is associated with a
twofold increase in the risk of hospitalisation for heart failure compared with diuretics alone.1
Moreover, ACE inhibitors, NSAIDs and diuretics, individually or in combination, are involved in
over 50% of cases of iatrogenic acute renal failure reported.
More specifically, the combined use of ACE inhibitors, diuretics and NSAIDs, termed the "triple
whammy", is implicated in a significant number of reports of drug-induced renal failure.2 This
effect is also seen with COX-2 inhibitors and angiotensin receptor antagonists ("sartans").3 In
2002, 28 of the 129 reports of acute renal failure implicated one of these combinations. Most
reports of drug-induced renal failure relate to elderly patients, and this applies as well to renal
failure associated with the triple therapy (median age 76 years). The fatality rate for cases of
renal failure with the "triple whammy" is 10%.
The use of ACE inhibitors and angiotensin receptor antagonists is increasing, as is the use of
these agents in combination products with a diuretic. Episodes of renal failure appear to be
precipitated by mild stress (e.g. diarrhoea, dehydration) in a patient taking the triple combination
or by the addition of a third drug (usually an NSAID) to the stable use of the other two.
It is therefore to remind prescribers that the combination of ACE inhibitors (or angiotensin
receptor antagonists), diuretics and NSAIDs (including COX-2 inhibitors) should be avoided if
possible, and great care should be taken with ACE inhibitors and NSAIDs in patients with renal
impairment.
References
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